Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Amortizatization of Intangibles of $17000.0 in Q1 2026, down 93.49% quarter-over-quarter from $261000.0 in Q4 2025, and down 94.16% on a YoY basis from $291000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Amortizatization of Intangibles history runs 12 years deep, the most recent figure standing at $17000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 94.16% year-over-year to $17000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 16.39% YoY), while the FY2025 annual figure was $1.3 million, up 17.88% from the prior year.
- Amortizatization of Intangibles was $17000.0 for Q1 2026 at Corvus Pharmaceuticals, down from $261000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $524000.0 in Q3 2024 to a low of -$83000.0 in Q3 2022.
- Historically, Amortizatization of Intangibles has averaged $209823.5 across 5 years, with a median of $242000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles sank 318.42% in 2022, then surged 545.0% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $158000.0 in 2022, then dropped by 19.62% to $127000.0 in 2023, then soared by 90.55% to $242000.0 in 2024, then gained by 7.85% to $261000.0 in 2025, then sank by 93.49% to $17000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $17000.0 (Q1 2026), $261000.0 (Q4 2025), and $459000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 261,000.00 |
| Dec 31, 2025 | 261,000.00 |
| Sep 30, 2025 | 459,000.00 |
| Sep 30, 2025 | 459,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Sep 30, 2024 | 524,000.00 |
| Sep 30, 2024 | 524,000.00 |
| Jun 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 224,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Dec 31, 2023 | 127,000.00 |
| Dec 31, 2023 | 127,000.00 |